SAFECARE® THC Urine Strip Test

K191924 · Safecare Biotech (Hangzhou) Co., Ltd. · NFW · Aug 16, 2019 · Clinical Toxicology

Device Facts

Record IDK191924
Device NameSAFECARE® THC Urine Strip Test
ApplicantSafecare Biotech (Hangzhou) Co., Ltd.
Product CodeNFW · Clinical Toxicology
Decision DateAug 16, 2019
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 862.3870
Device ClassClass 2

Indications for Use

SAFECARE® THC Urine Strip Test is a competitive binding, lateral flow immunochromatographic assay for qualitative detection of Marijuana in human urine at the cutoff concentrations of 50 ng/mL. The test provides only preliminary test results. A more specific alternative chemical must be used in order to obtain a confirmed analytical result. GC/MS or LC/MS is the preferred confirmatory method. The test is intended for over-the-counter use.

Device Story

Single-use lateral flow immunochromatographic assay; detects 11-nor-Δ9-THC-9 COOH in human urine. Principle: competitive binding; urine migrates via capillary action; target drug competes with drug-conjugate for limited antibody-coated particle binding sites. Output: visual colored line in test region (negative result) or absence of line (positive result); control line confirms test validity. Used in home/point-of-care settings by lay users. Provides preliminary results; requires confirmatory testing (GC/MS or LC/MS) for clinical decision-making. Benefits: rapid, accessible screening for marijuana metabolites.

Clinical Evidence

Bench testing only. Precision studies verified 50 ng/mL cutoff over 25 days. Interference testing confirmed no cross-reactivity with numerous physiological/pathological substances at 100µg/mL. Specificity testing evaluated cross-reactivity with THC metabolites. Method comparison study (n=80 clinical samples) showed high concordance with LC/MS. Lay-user study (n=140) demonstrated 90-100% accuracy across various concentrations relative to LC/MS, confirming ease of use and performance in intended user population.

Technological Characteristics

Lateral flow immunochromatographic assay; competitive binding principle. Uses monoclonal mouse antibody-coated particles. Form factor: test strip. Storage: 4-30°C. No electronic components, energy source, or software. Materials: standard immunochromatographic test strip components.

Indications for Use

Indicated for qualitative detection of Marijuana (11-nor-Δ9-THC-9 COOH) in human urine at 50 ng/mL cutoff. Intended for over-the-counter use by the general population.

Regulatory Classification

Identification

A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds include delta-9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.

Special Controls

*Classification.* Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Related Devices

Submission Summary (Full Text)

{0} 1 # 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION ## TRIAGE-QUICK REVIEW DECISION SUMMARY 510(k) Number: k191924 This 510(k) was reviewed under OIR’s Triage-Quick Review Program. This program represents an internal workload management tool intended to reduce internal FDA review resources for 510(k) applications that are of good quality upon receipt by FDA. The information in the 510(k) is complete and supports a substantial equivalence (SE) determination. Please refer to the applicant’s 510(k) summary for a summary of the information that supports this SE determination.
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...